DUPIXENT selectively targets a single signalling receptor, the IL-4Rα1,5
DUPIXENT thereby inhibits IL-4 and IL-13 signalling1,5,6
DUPIXENT reduces the persistent underlying Type 2 inflammation that specifically drives AD1,5
DUPIXENT helps to address clinical features of AD:4,5,7
DUPIXENT is a targeted immunomodulator which does not require routine lab monitoring1
AD, atopic dermatitis; IL, interleukin; IL-4Rα, interleukin 4 receptor alpha; ILC, innate lymphoid cells; Th, T-helper cells.